Satellos Bioscience Inc. (TSE:MSCL) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Satellos Bioscience Inc. reports unanimous shareholder approval for all director nominees and the adoption of key resolutions, including a reverse stock split, a new Equity Incentive Plan, and amendments to the company’s bylaws during its recent Annual and Special Meeting. The company, focused on developing treatments for muscle diseases, has a lead drug candidate for Duchenne muscular dystrophy and a proprietary discovery platform aimed at enhancing muscle repair and regeneration.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
